+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

EMulate Therapeutics Inc - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 37 Pages
  • December 2021
  • GlobalData
  • ID: 5519783
EMulate therapeutics Inc (EMulate therapeutics), formerly known as Nativis Inc, is a clinical stage bio-electronics company. The company provides portfolio of pipeline candidates which are under development for various therapeutic areas such as recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma, among others. Its lead product, EMulate therapeutics Voyager device is being evaluated for the treatment of recurrent glioblastoma multiforme (rGBM) brain tumors. Nativis’s Voyager device has possible treatment applications in a wide range of therapeutic areas such as cancer, chronic pain and inflammatory, among others. The company primarily provides treatment to patients with brain cancer. EMulate therapeutics is headquartered in Seattle, Washington, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:


  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company EMulate therapeutics Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:


  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

  • EMulate Therapeutics Inc Company Overview
  • EMulate Therapeutics Inc Company Snapshot
  • EMulate Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
  • EMulate Therapeutics Inc - Pipeline Analysis Overview
  • EMulate Therapeutics Inc - Key Facts
  • EMulate Therapeutics Inc - Major Products and Services
  • EMulate Therapeutics Inc Pipeline Products by Development Stage
  • EMulate Therapeutics Inc Ongoing Clinical Trials by Trial Status
  • EMulate Therapeutics Inc Pipeline Products Overview
  • Voyager ulRFE System - Diffuse Midline Glioma
  • Voyager ulRFE System - Diffuse Midline Glioma Product Overview
  • Voyager ulRFE System - Huntington's Disease
  • Voyager ulRFE System - Huntington's Disease Product Overview
  • Voyager ulRFE System - Immuno-oncology
  • Voyager ulRFE System - Immuno-oncology Product Overview
  • Voyager ulRFE System - Melanoma
  • Voyager ulRFE System - Melanoma Product Overview
  • Voyager ulRFE System - Newly Diagnosed GBM
  • Voyager ulRFE System - Newly Diagnosed GBM Product Overview
  • Voyager ulRFE System - Newly Diagnosed GBM Clinical Trial
  • Voyager ulRFE System - Pain
  • Voyager ulRFE System - Pain Product Overview
  • Voyager ulRFE System - Pediatric Patients
  • Voyager ulRFE System - Pediatric Patients Product Overview
  • Voyager ulRFE System - Recurrent Glioblastoma Multiforme
  • Voyager ulRFE System - Recurrent Glioblastoma Multiforme Product Overview
  • Voyager ulRFE System - Recurrent Glioblastoma Multiforme Clinical Trial
  • Voyager ulRFE System - Rheumatoid Arthritis
  • Voyager ulRFE System - Rheumatoid Arthritis Product Overview
  • Voyager ulRFE System - Solid Tumors
  • Voyager ulRFE System - Solid Tumors Product Overview
  • EMulate Therapeutics Inc - Key Competitors
  • EMulate Therapeutics Inc - Key Employees
  • EMulate Therapeutics Inc - Locations And Subsidiaries
  • Head Office
Recent Developments
  • EMulate Therapeutics Inc, Recent Developments
Nov 17, 2021: EMulate Therapeutics announces the incorporation of two wholly owned subsidiaries
Dec 08, 2020: Emulate announces Lung-Chip Technology used by U.S. Army to study effects of COVID-19
Aug 28, 2019: EMulate Therapeutics submits application for CE mark
Jul 31, 2019: EMulate Therapeutics reaches patent milestone
Jun 18, 2019: FDA accepts for filing the humanitarian device exemption application for EMulate Therapeutics Hælo Pediatric System
Mar 19, 2019: Nativis announces name change to Emulate Therapeutics
Feb 19, 2019: Nativis announces additional publication of further study in patients with recurrent glioblastoma
Dec 18, 2018: Nativis announces publication of study in patients with Recurrent Glioblastoma (rGBM)
Nov 14, 2018: Nativis announces early data from study in Treatment of Patients with newly diagnosed GBM
Aug 07, 2018: Nativis appoints Andrew Daniels to board of directors
Appendix
  • Methodology
  • About The Publisher
  • Contact The Publisher
  • Disclaimer

List of Tables
  • EMulate Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
  • EMulate Therapeutics Inc Pipeline Products by Equipment Type
  • EMulate Therapeutics Inc Pipeline Products by Indication
  • EMulate Therapeutics Inc Ongoing Clinical Trials by Trial Status
  • EMulate Therapeutics Inc, Key Facts
  • EMulate Therapeutics Inc, Major Products and Services
  • EMulate Therapeutics Inc Number of Pipeline Products by Development Stage
  • EMulate Therapeutics Inc Pipeline Products Summary by Development Stage
  • EMulate Therapeutics Inc Ongoing Clinical Trials by Trial Status
  • EMulate Therapeutics Inc Ongoing Clinical Trials Summary
  • Voyager ulRFE System - Diffuse Midline Glioma - Product Status
  • Voyager ulRFE System - Diffuse Midline Glioma - Product Description
  • Voyager ulRFE System - Huntington's Disease - Product Status
  • Voyager ulRFE System - Huntington's Disease - Product Description
  • Voyager ulRFE System - Immuno-oncology - Product Status
  • Voyager ulRFE System - Immuno-oncology - Product Description
  • Voyager ulRFE System - Melanoma - Product Status
  • Voyager ulRFE System - Melanoma - Product Description
  • Voyager ulRFE System - Newly Diagnosed GBM - Product Status
  • Voyager ulRFE System - Newly Diagnosed GBM - Product Description
  • Voyager ulRFE System - Newly Diagnosed GBM - A Feasibility Study of the Nativis Voyager System in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
  • Voyager ulRFE System - Pain - Product Status
  • Voyager ulRFE System - Pain - Product Description
  • Voyager ulRFE System - Pediatric Patients - Product Status
  • Voyager ulRFE System - Pediatric Patients - Product Description
  • Voyager ulRFE System - Recurrent Glioblastoma Multiforme - Product Status
  • Voyager ulRFE System - Recurrent Glioblastoma Multiforme - Product Description
  • Voyager ulRFE System - Recurrent Glioblastoma Multiforme - A Feasibility Study of the Nativis Voyager System in Patients with Recurrent Glioblastoma Multiforme (GBM)
  • Voyager ulRFE System - Rheumatoid Arthritis - Product Status
  • Voyager ulRFE System - Rheumatoid Arthritis - Product Description
  • Voyager ulRFE System - Solid Tumors - Product Status
  • Voyager ulRFE System - Solid Tumors - Product Description
  • EMulate Therapeutics Inc, Key Employees
  • Glossary

List of Figures
  • EMulate Therapeutics Inc Pipeline Products by Equipment Type
  • EMulate Therapeutics Inc Pipeline Products by Development Stage
  • EMulate Therapeutics Inc Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Seno Medical Instruments Inc
  • Mevion Medical Systems Inc
  • CivaTech Oncology Inc